Endoscopy Devices for Obesity, Type II Diabetes and NASH Market expected to reach $3.71 Billion by 2027

According to a new report published by Allied Market Research, titled, “Endoscopy Devices for Obesity, Type II Diabetes and NASH Market by Product, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2020–2028," the global endoscopy devices for obesity, type II diabetes and NASH market was valued at $2.63 billion in 2019, and is projected to reach $3.71 billion by 2028, registering a CAGR of 7.6% from 2021 to 2028. Endoscopy devices are the devices that aid in the viewing of internal organs within human body and capturing images which can be used for timely and accurate diagnosis of diseases, as well as aid in delivering drug therapies is the need for major surgeries and treatments. Endoscopic devices are either inserted into the body through natural openings or cavities (such as anus and mouth) or through incisions. These endoscopes can be used in treating conditions such as obesity, type II diabetes and non-alcoholic steatohepatitis. Advantages of using endoscopy devices in minimally invasive treatments include easy weight loss of the patient, lowering of the blood sugar level, reversibility of the process, and rare complications associated with the process.

The endoscopy devices for obesity, type II diabetes and NASH market is expected to experience significant growth during the forecast period, owing to increase in preference for minimally invasive endoscopic procedures and surge in geriatric population with ailments that need endoscopic procedures. Moreover, upsurge in obese population and comorbid conditions such as diabetes and NASH propel the growth of the market. Significant increase in prevalence of diabetes and rise in demand for endoscopy devices in diagnostic & therapeutic procedures drive the market growth. Use of endoscopic devices in diagnosis and treatment of obesity related conditions is essential as it enables minimal intervention, resulting in shorter recovery time. In addition, rise in adoption of endoscope and visualization systems in healthcare settings, coupled with technological advancements also foster the growth of the endoscopy devices for obesity, type II diabetes and NASH market.

By product type, the obesity, type II diabetes and NASH market is categorized into endoscope, mechanical endoscopic equipment, visualization and documentation systems, accessories, and other endoscopy equipment. The endoscope segment dominated the global market in 2019, and is anticipated to remain dominant during the forecast period. This is majorly attributed to the surge in use of endoscopes in minimally invasive procedures such as gastric balloon, endoscopic sleeve gastroplasty and lap band surgery. 

By procedure, endoscopy devices for obesity, type II diabetes and NASH market is segregated into gastric balloon, aspiration therapy, endoscopic sleeve gastroplasty, gastric injection and lap band surgery. At present, the endoscopic sleeve gastroplasty segment accounts for the majority of market share, owing to its advantages over other procedures. 

By disease indication, endoscopy devices for obesity, type II diabetes and NASH market is classified into obesity, type II diabetes and NASH. The diabetes segment is anticipated to garner the largest share, owing to surge in prevalence of diabetes among individuals and surge in developments of products and surgeries related to obesity in diabetic population. 

By region, Europe accounted for approximately 37.54% of the global endoscopy devices for obesity, type II diabetes, and NASH market share in 2019, and is expected to remain dominant throughout the forecast period. This was attributed to established healthcare infrastructure, surge in adoption of advanced technologies, increase in geriatric population, and rise in prevalence of obesity, diabetes as well as NASH in the region. Furthermore, Asia-Pacific is anticipated to register highest growth rate throughout the forecast period. This is majorly attributed to the improvement in health awareness, development in healthcare infrastructure, and rise in number of patients suffering from diabetes and obesity.

The report provides a comprehensive analysis of the key players that operate in the global Endoscopy Devices for Obesity, Type II Diabetes and NASH Market such as Apollo Endosurgery, Fractyl Laboratories, Gi Dynamics, Gi Windows, Aspire Bariatrics, Reshape LifeSciences, Inc., USGI Medical, Obalon Therapeutics, Spatz Fgia and Endo Tools Therapeutics.

Key Findings Of The Study

• By product type, the endoscope segment held more than 60.48% share in the global endoscopy devices for obesity, type II diabetes and NASH market in 2019.
• By procedure, the endoscopic sleeve gastroplasty segment held largest market share in 2019 and is expected to remain dominant throughout the forecast period.
• By disease indication, the type II diabetes segment exhibits fastest growth and is expected to grow at a CAGR of 8.0% from 2020 to 2028. 
• By region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 9.6% during the forecast period.